Table 1.
Clinical, demographic, laboratory features and outcomes of the whole population and of ATA versus PMMA group
| Variables | Total (74) | ATA (48) | PMMA (26) | p value |
|---|---|---|---|---|
| Age, year, mean (SD) | 68.30 (15.71) | 67.67 (15.48) | 69.46 (16.37) | 0.6421 |
| Male, n (%) | 51 (70) | 34 (71) | 17 (66) | 0.7930 |
| HD age, months, median (SD) | 43.50 (14.25–88.00) | 47.00 (13.75–89.75) | 27.50 (14.25–71.50) | 0.3653 |
| Charlson Comorbidity Index, median (IQR) | 4.50 (3.00–6.00) | 4.00 (3.00–5.00) | 5 (3.00–7.25) | 0.2549 |
| Vascular access, n (%) | ||||
| Arteriovenous fistula | 50 (67) | 36 (75) | 14 (54) | 0.0744 |
| Central venous catheter | 24 (33) | 12 (25) | 12 (46) | |
| Comorbidity | ||||
| CV disease, n (%) | 61 (82) | 39 (81) | 22 (84) | >0.9999 |
| DM, n (%) | 28 (37) | 15 (31) | 13 (50) | 0.1364 |
| Cancer, n (%) | 9 (12) | 5 (10) | 4 (15) | 0.7113 |
| BMI > 30 | 10 (14) | 4 (8) | 6 (23) | 0.1583 |
| Dialysis sessions, n | 611 | 420 | 191 | NA |
| Blood flow, mL/min, median (IQR) | 300 (250–300) | 300 (280–300) | 300 (250–300) | 0.1281 |
| Convective volume, L, median (IQR) | 18.30 (15.70–20.70) | 18.30 (15.35–21.20) | 18.30 (15.95–20.50) | 0.6747 |
| Respiratory failure, n (%) | 37 (50) | 22 (46) | 15 (58) | 0.8108 |
| Interstitial pneumonia, n (%) | 49 (66) | 29 (60) | 20 (77) | 0.2008 |
| Antibiotic therapy at diagnosis, n (%) | 35 (49) | 27 (56) | 8 (31) | 0.0512 |
| IL-6 RR%, median (IQR) | 14.55 (–15.13 to 36.71) | 17.08 (–9.0 to 40.0) | 2.95 (–34.63 to 27.32) | <0.001 |
| Pre-HD IL-6, pg/mL, median (IQR) | 14.30 (5.80–39.00) | 14.50 (5.75–41.43) | 13.90 (5.80–34.10) | 0.6386 |
| IL-6 RR% based on pre-dialysis IL-6 level | ||||
| 1st tertile, median (IQR) | 17.21 (–21.93 to 39.59) | 23.55 (–8.96 to 47.40) | 3.72 (–51.66 to 30.08) | 0.0013 |
| 2nd tertile median (IQR) | 13.13 (–14.40 to 34.91) | 16.69 (–9.79 to 39.39) | 2.18 (–24.03 to 25.95) | 0.0405 |
| 3rd tertile, median (IQR) | 12.10 (–14.63 to 34.76) | 12.99 (–8.73 to 35.75) | 1.14 (–34.70 to 31.33) | 0.0501 |
| CRP RR%, median (IQR) | 7.20 (0.15–13.04) | 7.77 (2.47–13.77) | 4.80 (–2.65 to 11.38) | 0.0017 |
| PCT-RR%, median (IQR) | 72.75 (58.86–80.18) | 77.38 (70.92–82.97) | 54.59 (42.62–63.16) | <0.0001 |
| Laboratory variables at diagnosis | ||||
| Hb, g/dL, median (IQR) | 10.90 (9.6–11.90) | 11.00 (9.70–12.10) | 10.30 (9.17–11.60) | 0.5985 |
| PLT, 109/L, median (IQR) | 186 (140–217) | 178 (144–221) | 191 (131–216) | 0.9363 |
| WBC, 109/L, median (IQR) | 5.17 (3.99–7.11) | 5.00 (3.90–6.57) | 6.50 (4.13–7.92) | 0.0974 |
| Lymphocytes, 109/L, median (IQR) | 0.65 (0.50–0.99) | 0.64 (0.48–0.90) | 0.75 (0.59–1.38) | 0.2064 |
| Eosinophils, 109/L, median (IQR) | 0.10 (0.03–0.33) | 0.09 (0.03 – 0–19) | 0.17 (0.04–0.60) | 0.3934 |
| IL-6, pg/mL, median (IQR) | 21.25 (9.22–56.48) | 20.30 (9.10–62.10) | 22.60 (9.80–56.35) | 0.8763 |
| CRP, mg/dL, median (IQR) | 3.30 (0.54–12.68) | 3.88 (0.77–143.70) | 3.30 (0.33–9.98) | 0.4134 |
| PCT, pg/mL, median (IQR) | 1.40 (0.63–2.58) | 1.60 (0.72–2.77) | 0.95 (0.53–1.48) | 0.0388 |
| Albumin, g/dL, median (IQR) | 32.20 (22.10–36.60) | 32.60 (28.70–37.40) | 32.00 (29.65–34.55) | 0.7105 |
CV, cardiovascular; DM, diabetes mellitus; BMI, body mass index; CRP, C-reactive protein; PCT, procalcitonin.